Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: better pain relief, sleep and physical health
- 3 September 2011
- journal article
- research article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 13 (9) , 656-663
Abstract
A previous study of cancer-related neuropathic pain (NP) found that a 10-fold increase in pregabalin (PGB) use increased patients’ satisfaction with treatment. Further research of PGB vs. non-pregabalin (non-PGB) treatment was carried out to assess if the use of more specific NP-targeting drugs, such as PGB, in combined therapy, in patients with cancer-related NP, provides better health outcomes.Keywords
This publication has 48 references indexed in Scilit:
- Effects of pregabalin on visceral pain responses and colonic compliance in ratsBritish Journal of Pharmacology, 2008
- Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramineSupportive Care in Cancer, 2008
- Barriers to pain assessment and management in cancer survivorshipJournal of Cancer Survivorship, 2008
- Symptom Clusters in Patients with Advanced-Stage Cancer Referred for Palliative Radiation Therapy in an Outpatient SettingSupportive Cancer Therapy, 2007
- Symptom clustering in advanced cancerSupportive Care in Cancer, 2006
- Pharmacologic Management Part 1: Better-Studied Neuropathic Pain DiseasesPain Medicine, 2004
- Problems Recruiting Cancer Patients to a Comparative Clinical Trial of Drug Treatments for Neuropathic Pain in Palliative CareJournal of Pain and Symptom Management, 2002
- A survey of pain in patients with advanced cancerJournal of Pain and Symptom Management, 1996
- The Risks and Benefits of Corticosteroids in Advanced CancerDrug Safety, 1994
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983